Ultrasound with microbubbles by Chris Harvey
ORAL PRESENTATION Open Access
Ultrasound with microbubbles
Chris Harvey
From International Cancer Imaging Society Meeting and 15th Annual Teaching Course (ICIS 2015)
London, UK. 5-7 October 2015
Conventional ultrasound has well known short comings
in the detection and characterisation of focal liver
lesions. A false negative rate of up to 30% has been
quoted in the detection of liver metastases and its accu-
racy in the characterisation of focal liver lesions is poor
compared to computed tomography (CT) and magnetic
resonance (MR). Ultrasound microbubble contrast
agents have redressed these limitations.
Ultrasound microbubbles have been available for over
20 years and are licensed for clinical use in most parts
of the world. The characterization of focal liver lesions
is the most important application of contrast-enhanced
US (CEUS), with an accuracy rivalling that of CT and
MR [1-8].
Microbubbles consist of a low solubility complex gas
such as a perfluoro gas surrounded by a phospholipid
shell. They are similar in size to red blood cells, in com-
parison to the molecular sizes of CT and MR contrast
agents. They are pure intravascular agents. Following an
intravenous injection they last in the circulation for
about 5 minutes. By good fortune, microbubbles resonate
in an ultrasound field at the frequencies used in everyday
diagnostic sonography. During resonance they emit
‘fingerprint like’ harmonic signals (overtones) which can
be selectively detected by the microbubble-specific soft-
ware available on commercial ultrasound systems. Micro-
bubbles are imaged using low acoustic power modes to
reduce their destruction and thus allow real-time ima-
ging. They are better tolerated than MR and CT agents
with fewer and less severe adverse effects and are not
nephrotoxic. The most widely used agent in Europe is
Sonovue (Bracco).
The liver demonstrates three phases of enhancement
after an i.v. bolus injection: the arterial, portal and late
phases. The late phase occurs as the vascular phases
subside, when the microbubbles are sequestered in the
sinusoids of the liver.
Enhancement is visualized in real time alongside a
B-mode greyscale image. The enhancement characteris-
tics of liver lesions at CEUS are similar to those seen on
CT and MR imaging. Since CEUS operates in real time,
fast changes during the arterial phase are better cap-
tured than on CT or MR.
This presentation discusses the enhancement character-
istics of malignant and benign liver lesions. As a general
rule, however, lesions which do not washout in the late
phase (i.e. remain hyperenhancing or isoenhancing to liver
parenchyma) tend to be benign (with the exception of
simple cysts, haematomas, ablation cavities and abscesses,
which do not enhancement in any phase), whereas lesions
which do not retain contrast in the late phase (i.e. demon-
strate washout) are usually malignant.
Hepatic metastases have variable appearances on
B-mode ultrasound. On CEUS, hypervascular metastases
typically demonstrate avid enhancement throughout the
lesion in the arterial phase whilst hypovascular metastases
show rim enhancement in the arterial phase with both
types showing washout in the late phases appearing as
defects. CEUS significantly increases the conspicuity of
metastases compared to B mode, allowing the detection of
isoechoic and lesions down to 3mm.
CEUS and intervention: The use of CEUS may allow
better visualisation of a lesion than on B-mode ultrasound
and allow a targeted ultrasound-guided biopsy.
CEUS may also be used during interstitial ablation of a
focal malignant liver lesion. The operator is able to per-
form repeated injections of microbubbles in order to
establish whether viable tumour remains, and whether
immediate further on-table ablative therapy is required.
Benign liver lesions have characteristic enhancement
patterns on CEUS. Haemangiomas demonstrate gradual
peripheral nodular enhancement with progressive centri-
petal filling whereas focal nodular hyperplasia typically
demonstrate avid arterial centrifugal enhancement in a
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“spoke wheel” pattern, arising from a central feeding ves-
sel and then become isoenhancing to liver by the late
phase.
Focal Fatty Sparing & Focal Fatty Change demon-
strate identical enhancement to the surrounding liver par-
enchyma in all phases of CEUS. CEUS can demonstrate
enhancing septa in abscesses. CEUS may indicate suitable
drainage sites.
In summary microbubbles have expanded the role of US
in the real-time characterisation of focal liver lesions based
on specific enhancement patterns to differentiate benign
and malignant lesions. Ultrasound contrast agents have
significantly improved the sensitivity and specificity of
ultrasound to rival that of CT and MR.
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